Physician profile
Reavis Bell
NPI 1427713536
$1,496.60
in general payments reported to CMS, 2019-2025
12 companies · $22.48 in 2025
The $22.48 reported for 2025 was less than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.33 · 2022: $175 · 2023: $1,251 · 2024: $34.31 · 2025: $22.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $800 · Food and Beverage: $508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $799.83 |
| Food and Beverage | $508.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $1,147.21 | 2023 | Axonics |
| Ultragenyx Pharmaceutical INC. | $63.69 | 2022 | |
| Mylan Specialty L.P. | $55.90 | 2022-2023 | Yupelri |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $50.43 | 2022 | |
| Xeris Pharmaceuticals, INC. | $38.03 | 2023 | Gvoke Hypopen |
| Abbvie INC. | $31.63 | 2022-2024 | |
| Becton, Dickinson and Company | $22.48 | 2025 | Bd Max System, Bd Max Instrument |
| Amgen INC. | $20.65 | 2024 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $20.30 | 2023 | Farxiga |
| Astellas Pharma US INC | $16.59 | 2023 | Myrbetriq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.36 | 2022 | |
| Medtronic, INC. | $13.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reavis Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.